This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Performance you can trust hero banner image

EYLEA® (aflibercept) 8 mg

Innovative Mechanism of Action

AFLIBERCEPT IS A VEGF-TRAP MOLECULE BUILT FROM NATIVE RECEPTOR DOMAINS

Aflibercept is a fusion protein built from portions of the native human receptors VEGFR-1 and VEGFR-2. It acts as a decoy receptor for VEGF-A, VEGF-B, PlGF and Gal-1.

 

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to macular oedema secondary to retinal vein occlusion (branch, central and hemiretinal RVO).

Aflibercept molecule

Aflibercept molecule

The rationale for testing a high molar dose

The rationale for testing a high molar dose_Day 0

This is a purely illustrative hypothesis for duration of effect of a higher molar dose vs a lower molar dose. Preclinical and clinical testing of an agent must be conducted to determine the safety, efficacy and durability profiles.

Keep VEGF supressed for longer vs EYLEA 2 mg*

EYLEA 8 mg is a 4x higher molar dose formulation of EYLEA 2 mg, a known molecule with an established safety profile, that can deliver rapid and long-lasting VEGF suppression

 

Model of logarithmic intraocular drug concentration over time*

Model of logaritmic intraocular drug concentration over time graph

The impact of molecular properties on clinical outcomes is yet to be defined. This is a hypothetical, illustrative model based on in vitro data and should be interpreted with caution.

34% slower
ocular clearance rate†

6 weeks longer
predicted VEGF suppression†

*Suppression is based on a PK/PD model.

†vs EYLEA 2 mg.

 

Prescribing information for EYLEA® (aflibercept)

can be found here
.

EYLEA 8 mg logo
EYLEA® (aflibercept) 8 mg
Discover data and resources about EYLEA 8 mg
PP-EYL-GB-3129, March 2026
EYLEA 8 mg dosing page content card
EYLEA® (aflibercept) 8 mg Dosing
Discover dosing of EYLEA® (aflibercept) 8 mg
PP-EYL-GB-3073, February 2026
EYLEA 8 mg PFS page content card
EYLEA® (aflibercept) 8 mg Pre-filled Syringe
Access resources for the EYLEA® (aflibercept) 8 mg Pre-filled Syringe
PP-EYL-GB-3078, March 2026

Abbreviations

DMO, diabetic macular oedema. EPAR, European public assessment report. Fc, fragment crystallisable. Gal-1, galectin-1. IgG, immunoglobulin G. nAMD, neovascular (wet) age-related macular degeneration. PK/PD, pharmacokinetic/pharmacodynamic. PIGF, placental growth factor. RVO, retinal vein occlusion. VEGF, vascular endothelial growth factor. VEGFR, vascular endothelial growth factor receptor.

PP-EYL-GB-3080 | March 2026

    • 1
      EYLEA® 114.3 mg/mL Summary of Product Characteristics.
    • 2
      Papadopoulos N, et al. Angiogenesis 2012;15:171–185.
    • 3
      Kanda A, et al. Sci Rep 2015;5:17946.
    • 4
      Schubert W, et al. Transl Vis Sci Technol 2022;11:36.
    • 5
      EMA. EYLEA EPAR assessment report 2023. Available at: https://www.ema.europa.eu/en/documents/variation-report/eylea-h-c-2392-x-84-g-epar-assessment-report-variation_en.pdf. Accessed: March 2026.
    • 6
      Kaiser P, et al. Population pharmacokinetic modeling and simulation of ocular clearance for aflibercept 8 mg and 2 mg and association with durability of effect. ARVO. 5–9 May 2024. Poster presentation.
    • 7
      Do D, et al. Retina 2020;40:643–647.
    • 8
      Veritti D, et al. Pharmaceutics 2023;15:1416.